Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €7.15, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 23x in the Biotechs industry in Europe. Total loss to shareholders of 83% over the past year. Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to €9.80, the stock trades at a trailing P/E ratio of 71.1x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 72% over the past year. Valuation Update With 7 Day Price Move • Jul 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €9.80, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 74% over the past year. New Risk • Jun 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 3.4% per year over the past 5 years. High level of non-cash earnings (111% accrual ratio). Board Change • May 21
High number of new directors Independent Director Michael Zhang was the last director to join the board, commencing their role in 2026. 공고 • Jan 27
Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026 Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004. 공고 • Oct 10
Anbio Biotechnology Showcases Diagnostic Portfolio At WSAVA 2025 Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets. At WSAVA 2025, Anbio displayed five product lines: Fluorescence Immunoassay (FIA); Dry Chemistry; Molecular Diagnostics; Colloidal Gold Rapid Tests; Dry Chemiluminescence Immunoassay (CLIA). The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemistry and fluorescence immunoassay systems were noted for their precision and usability, while discussions with distributors reflected demand for accessible and accurate testing technologies in veterinary healthcare. A key feature was Anbio's molecular diagnostics platform, capable of producing multi-target real-time PCR results within 15 minutes. This function was highlighted as a practical option for the rapid detection of respiratory and infectious diseases in animals, where timely results are critical to clinical management. Delegates pointed to the relevance of such technologies in strengthening outbreak response and supporting routine diagnostic workflows. The exhibition also provided opportunities for Anbio to engage with existing and potential partners, discuss distribution strategies, and consider future product rollouts. These exchanges underlined the increasing role of point-of-care diagnostics in veterinary practice and emphasized the importance of international collaboration in expanding access to diagnostic tools. Looking ahead, Anbio will continue its global outreach. The company is scheduled to participate in the Wild West Vet Show 2025, taking place from October 15-18, 2025, in Reno, Nevada, USA. The exhibition will provide another opportunity to present its veterinary diagnostic portfolio. Anbio's participation in WSAVA 2025 reflects its continuing efforts in both human and veterinary diagnostics. By advancing practical and reliable testing solutions, the company contributes to improving healthcare outcomes in diverse settings worldwide. 
